

Marshall 08/468161

=> d his

(FILE 'WPIDS' ENTERED AT 13:43:29 ON 22 JUL 1997)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 13:44:15 ON 22 JUL 1997

L1 45 S ANK[IA]SYQS[SA]S[TL]|RYQSSSL/SQSP
SAVE L1 TEMP MARSHALL/A
L2 STR
L3 50 S L2
L4 3608 S L3 FUL
L5 13 S L4 AND L1

FILE 'HCAPLUS' ENTERED AT 13:47:44 ON 22 JUL 1997

L6 3 S L5
L7 3 S L1 AND L4
L8 0 S L7 NOT L6

Marshall 08/468161

=> fil reg

FILE 'REGISTRY' ENTERED AT 13:49:16 ON 22 JUL 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 JULY 97 HIGHEST RN 191466-25-8
DICTIONARY FILE UPDATES: 21 JULY 97 HIGHEST RN 191466-25-8

TSCA INFORMATION NOW CURRENT THROUGH DECEMBER 1996

Please note that search-term pricing does apply when
conducting SmartSELECT searches.


=> d que 11

L1 45 SEA FILE=REGISTRY ABB=ON ANK[IA]SYQS[SA]S[TL]|RYQSSSL/SQ
SP

sea search

=> d que stat 14

L2 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RSPEC I

NUMBER OF NODES IS 27

STEREO ATTRIBUTES: NONE

L4 3608 SEA FILE=REGISTRY SSS FUL L2

structure search

100.0% PROCESSED 4889 ITERATIONS
SEARCH TIME: 00.00.08

3608 ANSWERS

=> d his 15

(FILE 'REGISTRY' ENTERED AT 13:44:15 ON 22 JUL 1997)

L5 13 S L4 AND L1

sea + struc together in 1 structure

=> d sqide3 1-13 15

L5 ANSWER 1 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 189513-11-9 REGISTRY

CN 5,12-Naphthacenedione, 10-[[[3-[[[N-[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginy]]-L-lysyl]-L-isoleucyl]-L-seryl]-L-tyrosyl]-L-glutaminy]]-L-seryl]-L-seryl]-L-seryl]-L-threonyl]-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 12

NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl
modification	-	undetermined modification

SEQ3 1 Ala-Asn-Lys-Ile-Ser-Tyr-Gln-Ser-Ser-Ser-
 == == == == == == == == ==
 11 Thr-Leu
 ==

HITS AT: 1-11


MF C84 H120 N16 O32 . C2 H F3 O2
 SR CA
 LC STN Files: CA, CAPLUS


CM 1

CRN 174640-85-8
 CMF C84 H120 N16 O32


Absolute stereochemistry.

PAGE 1-A






NH₂



CM 2

CRN 76-05-1

CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 2 OF 13 REGISTRY COPYRIGHT 1997 ACS

RN 189512-71-8 REGISTRY

CN 5,12-Naphthacenedione, 10-[[3-[[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginy]-L-lysyl]-L-alanyl]-L-seryl]-L-tyrosyl]-L-glutaminy]-L-seryl]-L-seryl]-L-seryl]-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-

Marshall 08/468161

6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-,
monoacetate (salt) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 11

NTE modified

type	-----	location	-----	description
terminal mod.		Ala-1	-	N-acetyl
modification		-	-	undetermined modification

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ser-Ser-

11 Leu

HITS AT: 1-11

MF C77 H107 N15 O30 . C2 H4 O2

SR CA

LC STN Files: CA, CAPLUS


CM 1


CRN 174640-88-1

CMF C77 H107 N15 O30

Absolute stereochemistry.


PAGE 1-A





CM 2

CRN 64-19-7
CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 3 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 189512-70-7 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginy]-L-lysyl]-L-alanyl]-L-seryl]-L-tyrosyl]-L-glutaminyl]-L-seryl]-L-alanyl]-L-seryl]-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl
modification	-	undetermined modification

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ala-Ser-
=====
11 Leu
=====
HITS AT: 1-11

Marshall 08/468161


MF C77 H107 N15 O29 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 174640-87-0
CMF C77 H107 N15 O29

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



CM 2

Marshall 08/468161

CRN 64-19-7
CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 4 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 189512-69-4 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginy]-L-lysyl]-L-alanyl]-L-seryl]-L-tyrosyl]-L-glutaminy]-L-seryl]-L-alanyl]-L-seryl]-L-threonyl]-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-, monoacetate (salt) (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 12
NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl
modification	-	undetermined modification

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ala-Ser-
=====
11 Thr-Leu
=====

HITS AT: 1-11


MF C81 H114 N16 O31 . C2 H4 O2
SR CA
LC STN Files: CA, CAPLUS

CM 1


CRN 174640-86-9
CMF C81 H114 N16 O31


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






CM 2

CRN 64-19-7

CMF C2 H4 O2



2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 5 OF 13 REGISTRY COPYRIGHT 1997 ACS

RN 189512-68-3 REGISTRY

CN L-Leucinamide, N-acetyl-L-alanyl-L-asparaginyll-L-lysyl-L-alanyl-L-seryl-L-tyrosyl-L-glutaminyll-L-seryl-L-seryl-L-seryl-L-threonyll-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 12

NTE modified

type	-----	location	-----	description
terminal mod.		Ala-1	-	N-acetyl
modification		-	-	undetermined modification

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ser-Ser-

=== === === === === === === === ===

11 Thr-Leu

===

HITS AT: 1-11

MF C81 H114 N16 O32 . C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS


CM 1



CRN 189512-67-2

CMF C81 H114 N16 O32

Absolute stereochemistry.


PAGE 1-A





CM 2

CRN 76-05-1
CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1967 TO DATE)
2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 6 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 189512-67-2 REGISTRY
CN L-Leucinamide, N-acetyl-L-alanyl-L-asparaginyl-L-lysyl-L-alanyl-L-seryl-L-tyrosyl-L-glutaminyl-L-seryl-L-seryl-L-seryl-L-threonyl-N-[2,3,6-trideoxy-1-O-[(1S,3S)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1-naphthacenyl]-.alpha.-L-lyxo-hexopyranos-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD; PROTEIN SEQUENCE; STEREOSEARCH
SQL 12
NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl


SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ser-Ser-
=====
11 Thr-Leu
=====

HITS AT: 1-11


MF C81 H114 N16 O32
CI COM
SR CA

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



L5 ANSWER 7 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 189512-66-1 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginy]l)-L-lysyl]-L-isoleucyl]-L-seryl]-L-tyrosyl]-L-glutaminy]l)-L-seryl]-L-seryl]-L-seryl]-L-threonyl]amino]-

Marshall 08/468161

2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-
6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-,
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 11

NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl
modification	-	undetermined modification

SEQ3 1 Ala-Asn-Lys-Ile-Ser-Tyr-Gln-Ser-Ser-Ser-

====

11 Thr

====

HITS AT: 1-11

MF C78 H109 N15 O31 . C2 H F3 O2

SR CA

LC STN Files: CA, CAPLUS


CM 1


CRN 174640-84-7

CMF C78 H109 N15 O31

Absolute stereochemistry.

PAGE 1-A






CM 2

CRN 76-05-1

CMF C2 H F3 O2



2 REFERENCES IN FILE CA (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 8 OF 13 REGISTRY COPYRIGHT 1997 ACS

RN 174640-88-1 REGISTRY

CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginyl]-L-lysyl]-L-alanyl]-L-seryl]-L-tyrosyl]-L-glutamyl]-L-seryl]-L-seryl]-L-seryl]-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 11

NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ser-Ser-

11 Leu

Marshall 08/468161

HITS AT: 1-11

MF C77 H107 N15 O30


CI COM

SR CA


LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 9 OF 13 REGISTRY COPYRIGHT 1997 ACS

RN 174640-87-0 REGISTRY

CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-

SQL 11

NTE modified

type	----- location -----	description
terminal mod.	Ala-1 -	N-acetyl

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ala-Ser-
 === === === === === === === === ===
11 Leu
 ===

HITS AT: 1-11

MF C77 H107 N15 O29


CI	COM
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100


SR CA

LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A





3 REFERENCES IN FILE CA (1967 TO DATE)

3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 10 OF 13 REGISTRY COPYRIGHT 1997 ACS

RN 174640-86-9 REGISTRY

CN 5,12-Naphthacenedione, 10-[[3-[[N-[[N-[[N-[[N-[[N-[[N2-[[N-[[N-[[N2-[[N2-(N-acetyl-L-alanyl)-L-asparaginy]-L-lysyl]-L-alanyl]-L-seryl]-L-tyrosyl]-L-glutaminy]-L-seryl]-L-alanyl]-L-seryl]-L-threonyl]-L-leucyl]amino]-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 12

NTE modified

type	location	description
terminal mod.	Ala-1	N-acetyl

SEQ3 1 Ala-Asn-Lys-Ala-Ser-Tyr-Gln-Ser-Ala-Ser-
 == == == == == == == == ==
 11 Thr-Leu
 ==

HITS AT: 1-11

MF C81 H114 N16 O31


CI COM

SR CA


LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 11 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 174640-85-8 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[[N-[[N-[[N-[[N-[[N2-[[N-[[N-[[N2-[[N2-((N-acetyl-L-alanyl)-L-asparaginy]-L-lysyl)-L-isoleucyl)-L-seryl)-L-tyrosyl)-L-glutaminy]-L-seryl)-L-seryl)-L-seryl)-L-threonyl)-L-leucyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 12
NTE modified



type	location	description
terminal mod.	Ala-1	N-acetyl

SEQ3 1 Ala-Asn-Lys-Ile-Ser-Tyr-Gln-Ser-Ser-Ser-
=====
11 Thr-Leu
=====


HITS AT: 1-11

MF C84 H120 N16 O32
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.



—NH₂



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 12 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 174640-84-7 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[N-[N-[N-[N2-[N-[N-[N-[N2-[N2-(N-acetyl-L-alanyl)-L-asparaginy]]-L-lysyl]-L-isoleucyl]-L-seryl]-L-tyrosyl]-L-glutaminy]]-L-seryl]-L-seryl]-L-seryl]-L-threonyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 11
NTE modified


type	location	description
terminal mod.	Ala-1	N-acetyl

SEQ3 1 Ala-Asn-Lys-Ile-Ser-Tyr-Gln-Ser-Ser-Ser-
====
11 Thr
====
HITS AT: 1-11


MF C78 H109 N15 O31
CI COM
SR CA
LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



3 REFERENCES IN FILE CA (1967 TO DATE)
3 REFERENCES IN FILE CAPLUS (1967 TO DATE)

L5 ANSWER 13 OF 13 REGISTRY COPYRIGHT 1997 ACS
RN 174640-83-6 REGISTRY
CN 5,12-Naphthacenedione, 10-[[3-[[N-[[N-[[N-[[N-[[N-[[N2-[[N-[[N-[[N-[[N2-((N2-L-alanyl-L-asparaginy)-L-lysyl)-L-isoleucyl)-L-seryl)-L-tyrosyl)-L-glutaminy)-L-seryl)-L-seryl)-L-seryl)-L-threonyl)-L-.alpha.-glutamyl]amino]-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 12
NTE modified

Marshall 08/468161

SEQ3 1 Ala-Asn-Lys-Ile-Ser-Tyr-Gln-Ser-Ser-Ser-
 === === === === === === === ===
 11 Thr-Glu
 ===

HITS AT: 1-11


MF C81 H114 N16 O33

SR CA


LC STN Files: CA, CAPLUS, TOXLIT, USPATFULL


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





1 REFERENCES IN FILE CA (1967 TO DATE)
1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 13:50:40 ON 22 JUL 1997
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 22 Jul 1997 VOL 127 ISS 4
FILE LAST UPDATED: 22 Jul 1997 (970722/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his l6-

(FILE 'HCAPLUS' ENTERED AT 13:47:44 ON 22 JUL 1997)

L6 3 S L5
L7 3 S L1 AND L4
L8 0 S L7 NOT L6

FILE 'REGISTRY' ENTERED AT 13:49:16 ON 22 JUL 1997

FILE 'HCAPLUS' ENTERED AT 13:50:40 ON 22 JUL 1997

=> d all l6

L6 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 1997 ACS
AN 1997:374825 HCAPLUS

Marshall 08/468161

DN 126:343882
TI Preparation of peptide conjugates useful in the treatment of benign
prostatic hyperplasia
IN Defeo-Jones, Deborah; Jones, Raymond E.; Oliff, Allen I.; Scolnick,
Edward M.; Garsky, Victor M.
PA Merck and Co., Inc., USA; Defeo-Jones, Deborah; Jones, Raymond E.;
Oliff, Allen I.; Scolnick, Edward M.; Garsky, Victor M.
SO PCT Int. Appl., 193 pp.
CODEN: PIXXD2
PI WO 9714416 A1 970424
DS W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU,
IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,
NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 96-US16490 961015
PRAI US 95-5664 951018
GB 96-2903 960213
DT Patent
LA English
IC ICM A61K031-40
ICS A61K031-44; A61K031-70; A61K038-02; A61K038-07; A61K038-08;
A61K038-10; A61K038-14
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 26, 63
OS MARPAT 126:343882
AB Novel pharmaceutical compns. useful for the treatment of benign
prostatic hyperplasia which comprises novel oligopeptides, which are
selectively cleaved by enzymically active prostate specific antigen
(PSA), in conjunction with a cytotoxic agent are described. Methods
of treating benign prostate hypertrophy are also disclosed. Thus,
doxorubicin (Dox) conjugate Ac-Lys-Tyr-Gln-Ser-Ser-Ser-Leu-Dox was
prepd. and assayed for recognition by free PSA (98% cleavage after 4
h).
ST peptide conjugate prepn prostate hyperplasia treatment; prostate
specific antigen cleavage peptide conjugate
IT Prostatic hyperplasia
(benign; prepn. of peptide conjugates for treatment of benign
prostatic hyperplasia)
IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(conjugates; prepn. of peptide conjugates for treatment of benign
prostatic hyperplasia)
IT Nucleosides, preparation
RL: BAC (Biological activity or effector, except adverse); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(cytotoxic, peptide conjugates; prepn. of peptide conjugates for
treatment of benign prostatic hyperplasia)
IT Anthracyclines
Enediynes
Taxanes
RL: BAC (Biological activity or effector, except adverse); SPN
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological
study); PREP (Preparation); USES (Uses)
(peptide conjugates; prepn. of peptide conjugates for treatment

of benign prostatic hyperplasia)

IT Prostate diseases
(prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT Prostate-specific antigen
RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
(prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT Alkaloids, preparation
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(vincaleukoblastine, peptide conjugates; prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT 91-18-9DP, Pteridine, peptide conjugates
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drugs; prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT 50-07-7DP, Mitomycin C, peptide conjugates 50-18-0DP, Cyclophosphamide, peptide conjugates 50-44-2DP, 6-Mercaptopurine, peptide conjugates 51-21-8DP, 5-Fluorouracil, peptide conjugates 54-62-6DP, Aminopterin, peptide conjugates 57-22-7DP, Vincristine, peptide conjugates 59-05-2DP, Methotrexate, peptide conjugates 147-94-4DP, Cytosine arabinoside, peptide conjugates 148-82-3DP, Melphalan, peptide conjugates 518-28-5DP, Podophyllotoxin, peptide conjugates 528-74-5DP, Dichloromethotrexate, peptide conjugates 801-52-5DP, Porfiromycin, peptide conjugates 865-21-4DP, Vinblastine, peptide conjugates 2410-93-7DP, Methopterin, peptide conjugates 2998-57-4DP, Estramustine, peptide conjugates 3352-69-0DP, Desacetylvinblastine, peptide conjugates 11056-06-7DP, Bleomycin, peptide conjugates 15228-71-4DP, Leurosidine, peptide conjugates 15663-27-1DP, Cisplatin, peptide conjugates 20830-81-3DP, Daunorubicin, peptide conjugates 23214-92-8DP, Doxorubicin, peptide conjugates 23360-92-1DP, Leurosine, peptide conjugates 33069-62-4DP, Taxol, peptide conjugates 33419-42-0DP, Etoposide, peptide conjugates 39472-31-6DP, Carminomycin, peptide conjugates 52081-33-1DP, Mitomycins, peptide conjugates 53643-48-4DP, Vindesine, peptide conjugates 117091-64-2DP, Etoposide phosphate, peptide conjugates 123165-35-5P 174640-89-2P 174640-90-5P 189509-08-8P 189509-11-3P 189509-93-1P 189510-36-9P 189510-41-6P 189510-44-9P 189510-46-1P 189510-54-1P 189510-62-1P 189510-64-3P 189510-66-5P 189510-68-7P 189510-70-1P 189510-74-5P 189510-76-7P 189510-78-9P 189510-80-3P 189510-86-9P 189510-89-2P 189510-91-6P 189510-93-8P 189510-95-0P 189510-97-2P 189510-99-4P 189511-01-1P 189511-03-3P 189511-06-6P 189511-11-3P 189511-16-8P 189511-19-1P 189511-22-6P 189511-27-1P 189511-30-6P 189511-32-8P 189511-34-0P 189511-38-4P 189511-41-9P 189511-44-2P 189511-47-5P 189511-50-0P 189511-52-2P 189511-54-4P 189511-57-7P 189511-59-9P 189511-62-4P 189511-64-6P 189511-66-8P 189511-69-1P 189511-71-5P 189511-75-9P 189511-77-1P 189511-79-3P 189511-81-7P 189511-83-9P 189511-85-1P 189511-86-2P 189511-87-3P 189511-89-5P 189511-90-8P 189511-92-0P 189511-95-3P 189511-98-6P 189512-00-3P 189512-02-5P 189512-07-0P

Marshall 08/468161

189512-10-5P	189512-12-7P	189512-15-0P	189512-17-2P
189512-19-4P	189512-21-8P	189512-22-9P	189512-23-0P
189512-24-1P	189512-25-2P	189512-26-3P	189512-27-4P
189512-28-5P	189512-29-6P	189512-30-9P	189512-32-1P
189512-34-3P	189512-35-4P	189512-37-6P	189512-38-7P
189512-39-8P	189512-40-1P	189512-41-2P	189512-42-3P
189512-43-4P	189512-44-5P	189512-45-6P	189512-46-7P
189512-47-8P	189512-48-9P	189512-50-3P	189512-52-5P
189512-53-6P	189512-54-7P	189512-55-8P	189512-57-0P
189512-59-2P	189512-60-5P	189512-61-6P	189512-62-7P
189512-63-8P	189512-65-0P	189512-66-1P	

189512-68-3P 189512-69-4P 189512-70-7P

189512-71-8P	189512-72-9P	189512-73-0P	189512-74-1P
189512-76-3P	189512-78-5P	189512-79-6P	189512-80-9P
189512-81-0P	189512-82-1P	189512-85-4P	189512-87-6P
189512-90-1P	189512-91-2P	189512-92-3P	189512-93-4P
189512-94-5P	189512-95-6P	189512-96-7P	189512-97-8P
189512-98-9P	189513-00-6P	189513-01-7P	189513-11-9P
189513-13-1P	189513-14-2P	189513-16-4P	189513-18-6P
189513-20-0P	189513-22-2P	189513-23-3P	189513-80-2P
189808-93-3P	189808-94-4P	189808-95-5P	

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT 143-67-9, Vinblastine sulfate 23214-92-8, Doxorubicin

RL: RCT (Reactant)

(prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT 55324-86-2P	55383-37-4P	130063-03-5P	189512-99-0P
189513-02-8DP, resin-bound		189513-03-9P	189513-04-0P
189513-05-1P	189513-07-3DP, resin-bound		189513-09-5P
189513-10-8P			

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of peptide conjugates for treatment of benign prostatic hyperplasia)

IT 123105-77-1P	174639-47-5P	174639-48-6P	174639-54-4P
174639-56-6P	174639-59-9P	174639-60-2P	174639-62-4P
174639-66-8P	174639-67-9P	174639-69-1P	174639-70-4P
174639-71-5P	174639-72-6P	174639-73-7P	174639-80-6P
174639-81-7P	174639-82-8P	174639-83-9P	174639-84-0P
174639-85-1P	174639-87-3P	174640-33-6P	174640-51-8P
174640-61-0P	174640-62-1P	174640-63-2P	174640-65-4P
174640-66-5P	174640-67-6P	174640-69-8P	174640-70-1P
174640-71-2P	174640-72-3P	174640-73-4P	174640-74-5P

174640-84-7P 174640-85-8P 174640-86-9P

174640-87-0P 174640-88-1P 174640-91-6P

174640-92-7P	174640-93-8P	189508-78-9P	189508-79-0P
189508-80-3P	189508-81-4P	189508-82-5P	189508-83-6P
189508-84-7P	189508-85-8P	189508-88-1P	189508-89-2P
189508-90-5P	189508-91-6P	189508-92-7P	189508-93-8P
189508-94-9P	189508-97-2P	189508-98-3P	189508-99-4P
189509-00-0P	189509-02-2P	189509-03-3P	189509-04-4P
189509-05-5P	189509-06-6P	189509-07-7P	189509-09-9P
189509-12-4P	189509-14-6P	189509-15-7P	189509-18-0P
189509-19-1P	189509-20-4P	189509-21-5P	189509-31-7P
189509-37-3P	189509-39-5P	189509-40-8P	189509-41-9P
189509-42-0P	189509-43-1P	189509-44-2P	189509-45-3P

Marshall 08/468161

189509-47-5P	189509-48-6P	189509-49-7P	189509-51-1P
189509-53-3P	189509-55-5P	189509-57-7P	189509-60-2P
189509-63-5P	189509-65-7P	189509-67-9P	189509-69-1P
189509-71-5P	189509-73-7P	189509-75-9P	189509-77-1P
189509-79-3P	189509-81-7P	189509-83-9P	189509-85-1P
189509-87-3P	189509-89-5P	189509-91-9P	189509-96-4P
189509-98-6P	189510-00-7P	189510-02-9P	189510-04-1P
189510-06-3P	189510-08-5P	189510-10-9P	189510-13-2P
189510-15-4P	189510-18-7P	189510-22-3P	189510-24-5P
189510-27-8P	189510-29-0P	189510-32-5P	189510-34-7P
189510-49-4P	189510-58-5P	189510-60-9P	189510-72-3P
189510-82-5P	189510-84-7P	189513-24-4P	189513-25-5P
189808-92-2P			

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(prepn. of peptide conjugates for treatment of benign prostatic
hyperplasia)

=> d all 16 2-3

L6 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 1997 ACS
AN 1997:369645 HCAPLUS
DN 126:343876
TI Novel peptides for treatment of prostate cancer
IN Defeo-Jones, Deborah; Feng, Dong-mei; Garsky, Victor M.; Jones,
Raymond E.; Oliff, Allen I.
PA Merck and Co., Inc., USA; Defeo-Jones, Deborah; Feng, Dong-Mei;
Garsky, Victor M.; Jones, Raymond E.; Oliff, Allen I.
SO PCT Int. Appl., 188 pp.
CODEN: PIXXD2
PI WO 9712624 A1 970410
DS W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU,
IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX,
NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,
GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 96-US15713 961002
PRAI US 95-540412 951006
DT Patent
LA English
IC ICM A61K038-00
ICS C07K005-10; C07K007-06; C07K014-00
CC 34-3 (Amino Acids, Peptides, and Proteins)
Section cross-reference(s): 1, 26, 63
OS MARPAT 126:343876
AB Oligopeptides which comprise amino acid sequences that are
recognized and proteolytically cleaved by free prostate specific
antigen (PSA) are described. Also described are assays which
comprise such oligopeptides useful for detg. free PSA protease
activity in vitro and in vivo. Therapeutic agents which comprise
conjugates of such oligopeptides and known cytotoxic agents are also
described. Thus, doxorubicin (Dox) conjugate Ac-Lys-Tyr-Gln-Ser-Ser-
Ser-Leu-Dox was prepd. and assayed for recognition by free PSA (98%
cleavage after 4 h).
ST peptide conjugate prepn prostate cancer treatment
IT Antitumor agents
Prostatic tumors
(peptides for treatment of prostate cancer)

Marshall 08/468161

IT Peptides, preparation
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides for treatment of prostate cancer)

IT Prostate-specific antigen
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptides for treatment of prostate cancer)

IT 123165-35-5P 174640-89-2P 174640-90-5P 189509-08-8P
189509-11-3P 189509-93-1P 189510-36-9P 189510-41-6P
189510-44-9P 189510-46-1P 189510-54-1P 189510-62-1P
189510-64-3P 189510-66-5P 189510-68-7P 189510-70-1P
189510-74-5P 189510-76-7P 189510-78-9P 189510-80-3P
189510-86-9P 189510-89-2P 189510-91-6P 189510-93-8P
189510-95-0P 189510-97-2P 189510-99-4P 189511-01-1P
189511-03-3P 189511-06-6P 189511-11-3P 189511-16-8P
189511-19-1P 189511-22-6P 189511-27-1P 189511-30-6P
189511-32-8P 189511-34-0P 189511-38-4P 189511-41-9P
189511-44-2P 189511-47-5P 189511-50-0P 189511-52-2P
189511-54-4P 189511-57-7P 189511-59-9P 189511-62-4P
189511-64-6P 189511-66-8P 189511-69-1P 189511-71-5P
189511-75-9P 189511-77-1P 189511-79-3P 189511-81-7P
189511-83-9P 189511-85-1P 189511-86-2P 189511-87-3P
189511-89-5P 189511-90-8P 189511-92-0P 189511-95-3P
189511-98-6P 189512-00-3P 189512-02-5P 189512-07-0P
189512-10-5P 189512-12-7P 189512-15-0P 189512-17-2P
189512-19-4P 189512-21-8P 189512-22-9P 189512-23-0P
189512-24-1P 189512-25-2P 189512-26-3P 189512-27-4P
189512-28-5P 189512-29-6P 189512-30-9P 189512-32-1P
189512-34-3P 189512-35-4P 189512-37-6P 189512-38-7P
189512-39-8P 189512-40-1P 189512-41-2P 189512-42-3P
189512-43-4P 189512-44-5P 189512-45-6P 189512-46-7P
189512-47-8P 189512-48-9P 189512-50-3P 189512-52-5P
189512-53-6P 189512-54-7P 189512-55-8P 189512-57-0P
189512-59-2P 189512-60-5P 189512-61-6P 189512-62-7P
189512-63-8P 189512-65-0P **189512-66-1P**
189512-68-3P 189512-69-4P 189512-70-7P
189512-71-8P 189512-72-9P 189512-73-0P 189512-74-1P
189512-76-3P 189512-78-5P 189512-79-6P 189512-80-9P
189512-81-0P 189512-82-1P 189512-85-4P 189512-87-6P
189512-90-1P 189512-91-2P 189512-92-3P 189512-93-4P
189512-94-5P 189512-95-6P 189512-96-7P 189512-97-8P
189512-98-9P 189513-00-6P 189513-01-7P **189513-11-9P**
189513-13-1P 189513-14-2P 189513-16-4P 189513-18-6P
189513-20-0P 189513-22-2P 189513-23-3P 189513-80-2P
189808-93-3P 189808-94-4P 189808-95-5P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(peptides for treatment of prostate cancer)

IT 143-67-9, Vinblastine sulfate 23214-92-8, Doxorubicin
RL: RCT (Reactant)
(peptides for treatment of prostate cancer)

IT 55324-86-2P 55383-37-4P 130063-03-5P 189512-99-0P
189513-02-8DP, resin-bound 189513-03-9P 189513-04-0P
189513-05-1P 189513-07-3DP, resin-bound 189513-09-5P
189513-10-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(peptides for treatment of prostate cancer)

Marshall 08/468161

IT 123105-77-1P 174639-47-5P 174639-48-6P 174639-54-4P
174639-56-6P 174639-59-9P 174639-60-2P 174639-62-4P
174639-66-8P 174639-67-9P 174639-69-1P 174639-70-4P
174639-71-5P 174639-72-6P 174639-73-7P 174639-80-6P
174639-81-7P 174639-82-8P 174639-83-9P 174639-84-0P
174639-85-1P 174639-87-3P 174640-33-6P 174640-51-8P
174640-61-0P 174640-62-1P 174640-63-2P 174640-65-4P
174640-66-5P 174640-67-6P 174640-69-8P 174640-70-1P
174640-71-2P 174640-72-3P 174640-73-4P 174640-74-5P

174640-84-7P 174640-85-8P 174640-86-9P

174640-87-0P 174640-88-1P 174640-91-6P

174640-92-7P 174640-93-8P 189508-78-9P 189508-79-0P
189508-80-3P 189508-81-4P 189508-82-5P 189508-83-6P
189508-84-7P 189508-85-8P 189508-88-1P 189508-89-2P
189508-90-5P 189508-91-6P 189508-92-7P 189508-93-8P
189508-94-9P 189508-97-2P 189508-98-3P 189508-99-4P
189509-00-0P 189509-02-2P 189509-03-3P 189509-04-4P
189509-05-5P 189509-06-6P 189509-07-7P 189509-09-9P
189509-12-4P 189509-14-6P 189509-15-7P 189509-18-0P
189509-19-1P 189509-20-4P 189509-21-5P 189509-31-7P
189509-37-3P 189509-39-5P 189509-40-8P 189509-41-9P
189509-42-0P 189509-43-1P 189509-44-2P 189509-45-3P
189509-47-5P 189509-48-6P 189509-49-7P 189509-51-1P
189509-53-3P 189509-55-5P 189509-57-7P 189509-60-2P
189509-63-5P 189509-65-7P 189509-67-9P 189509-69-1P
189509-71-5P 189509-73-7P 189509-75-9P 189509-77-1P
189509-79-3P 189509-81-7P 189509-83-9P 189509-85-1P
189509-87-3P 189509-89-5P 189509-91-9P 189509-96-4P
189509-98-6P 189510-00-7P 189510-02-9P 189510-04-1P
189510-06-3P 189510-08-5P 189510-10-9P 189510-13-2P
189510-15-4P 189510-18-7P 189510-22-3P 189510-24-5P
189510-27-8P 189510-29-0P 189510-32-5P 189510-34-7P
189510-49-4P 189510-58-5P 189510-60-9P 189510-72-3P
189510-82-5P 189510-84-7P 189513-24-4P 189513-25-5P
189808-92-2P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(peptides for treatment of prostate cancer)

L6 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 1997 ACS
AN 1996:177894 HCAPLUS
DN 124:220505
TI Novel oligopeptides for diagnosis and treatment of prostate cancer
IN DeFeo-Jones, Deborah; Feng, Dong-Mei; Garsky, Victor M.; Jones,
Raymond E.; Oliff, Allen I.
PA Merck and Co., Inc., USA
SO PCT Int. Appl., 141 pp.
CODEN: PIXXD2
PI WO 9600503 A1 960111
DS W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG,
KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG,
SI, SK, TJ, TM, TT, UA, US, UZ
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR,
IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG
AI WO 95-US8156 950607
PRAI US 94-267092 940628
US 95-404833 950315
DT Patent
LA English

IC ICM A61K038-00
ICS C07K001-00; C07K007-06; C07K007-08; C07K014-00; C12Q001-00;
C12Q001-37

CC 1-6 (Pharmacology)
Section cross-reference(s): 63

OS MARPAT 124:220505

AB Oligopeptides that are recognized and proteolytically cleaved by
free prostate specific antigen (PSA) are provided. Such
oligopeptides are useful for detg. free PSA protease activity in
vitro and in vivo for monitoring the treatment of adenocarcinoma of
protease,. Therapeutic agents which comprise conjugates of such
oligopeptides and known cytotoxic agents are also described.

ST oligopeptide prostate cancer diagnosis antitumor; assay prostate
specific antigen oligopeptide

IT Antigens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PSA (prostate-specific antigen), oligopeptide substrate of free
prostate specific antigen for diagnosis and treatment of prostate
cancer)

IT Prostate gland
(neoplasm, oligopeptide substrate of free prostate specific
antigen for diagnosis of)

IT Prostate gland
(neoplasm, adenocarcinoma, inhibitors, cytotoxic agents
conjugates with oligopeptide substrate of free prostate specific
antigen for)

IT Peptides, biological studies
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(oligo-, oligopeptide substrate of free prostate specific antigen
for diagnosis and treatment of prostate cancer)

IT Neoplasm inhibitors
(prostate gland adenocarcinoma, cytotoxic agents conjugates with
oligopeptide substrate of free prostate specific antigen for)

IT 174640-78-9P 174640-79-0P 174640-80-3P 174640-81-4P
174640-82-5P **174640-83-6P 174640-84-7P**
174640-85-8P 174640-86-9P 174640-87-0P
174640-88-1P 174640-89-2P 174640-90-5P 174640-91-6P
174640-92-7P 174640-93-8P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(doxorubicin conjugates with oligopeptide substrate of free
prostate specific antigen; treatment of prostate cancer using)

IT 174594-63-9P 174639-47-5P 174639-48-6P 174639-49-7P
174639-50-0P 174639-51-1P 174639-52-2P 174639-53-3P
174639-54-4P 174639-55-5P 174639-56-6P 174639-57-7P
174639-58-8P 174639-59-9P 174639-60-2P 174639-61-3P
174639-62-4P 174639-63-5P 174639-64-6P 174639-65-7P
174639-66-8P 174639-67-9P 174639-68-0P 174639-69-1P
174639-70-4P 174639-71-5P 174639-72-6P 174639-73-7P
174639-74-8P 174639-75-9P 174639-76-0P 174639-77-1P
174639-78-2P 174639-79-3P 174639-80-6P 174639-81-7P
174639-82-8P 174639-83-9P 174639-84-0P 174639-85-1P
174639-86-2P 174639-87-3P 174639-88-4P 174639-89-5P
174639-90-8P 174639-91-9P 174639-92-0P 174639-93-1P
174639-94-2P 174639-95-3P 174639-96-4P 174639-97-5P
174639-98-6P 174639-99-7P 174640-00-7P 174640-01-8P
174640-02-9P 174640-03-0P 174640-04-1P 174640-05-2P
174640-06-3P 174640-07-4P 174640-08-5P 174640-09-6P

174640-10-9P	174640-11-0P	174640-12-1P	174640-13-2P
174640-14-3P	174640-15-4P	174640-16-5P	174640-17-6P
174640-18-7P	174640-19-8P	174640-20-1P	174640-21-2P
174640-22-3P	174640-23-4P	174640-24-5P	174640-25-6P
174640-26-7P	174640-27-8P	174640-28-9P	174640-29-0P
174640-30-3P	174640-31-4P	174640-32-5P	174640-33-6P
174640-34-7P	174640-35-8P	174640-36-9P	174640-37-0P
174640-38-1P	174640-39-2P	174640-40-5P	174640-41-6P
174640-42-7P	174640-43-8P	174640-44-9P	174640-45-0P
174640-46-1P	174640-47-2P	174640-48-3P	174640-49-4P
174640-50-7P	174640-51-8P	174640-52-9P	174640-53-0P
174640-54-1P	174640-55-2P	174640-56-3P	174640-57-4P
174640-58-5P	174640-59-6P	174640-60-9P	174640-61-0P
174640-62-1P	174640-63-2P	174640-64-3P	174640-65-4P
174640-66-5P	174640-67-6P	174640-68-7P	174640-69-8P
174640-70-1P	174640-71-2P	174640-72-3P	174640-73-4P
174640-74-5P	174640-75-6P	174640-76-7P	174640-77-8P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(oligopeptide substrate of free prostate specific antigen; diagnosis and treatment of prostate cancer using)

IT 50-07-7D, Mitomycin c, conjugates with oligopeptide substrate of free prostate specific antigen 50-18-0D, Cyclophosphamide, conjugates with oligopeptide substrate of free prostate specific antigen 50-44-2D, 6-Mercaptopurine, conjugates with oligopeptide substrate of free prostate specific antigen 51-21-8D, 5-Fluorouracil, conjugates with oligopeptide substrate of free prostate specific antigen 54-62-6D, Aminopterin, conjugates with oligopeptide substrate of free prostate specific antigen 57-22-7D, Vincristine, conjugates with oligopeptide substrate of free prostate specific antigen 59-05-2D; Methotrexate, conjugates with oligopeptide substrate of free prostate specific antigen 147-94-4D, Cytosine arabinoside, conjugates with oligopeptide substrate of free prostate specific antigen 148-82-3D, Melphalan, conjugates with oligopeptide substrate of free prostate specific antigen 518-28-5D, Podophyllotoxin, conjugates with oligopeptide substrate of free prostate specific antigen 528-74-5D, Dichloro-methotrexate, conjugates with oligopeptide substrate of free prostate specific antigen 801-52-5D, Porfiromycin, conjugates with oligopeptide substrate of free prostate specific antigen 865-21-4D, Vinblastine, conjugates with oligopeptide substrate of free prostate specific antigen 2410-93-7D, Methopterin, conjugates with oligopeptide substrate of free prostate specific antigen 2998-57-4D, Estramustine, conjugates with oligopeptide substrate of free prostate specific antigen 15228-71-4D, Leurosidine, conjugates with oligopeptide substrate of free prostate specific antigen 15663-27-1D, Cisplatin, conjugates with oligopeptide substrate of free prostate specific antigen 20830-81-3D, Daunorubicin, conjugates with oligopeptide substrate of free prostate specific antigen 23214-92-8D, Doxorubicin, conjugates with oligopeptide substrate of free prostate specific antigen 23360-92-1D, Leurosine, conjugates with oligopeptide substrate of free prostate specific antigen 33419-42-0D, Etoposide, conjugates with oligopeptide substrate of free prostate specific antigen 39472-31-6D, Carminomycin, conjugates with oligopeptide substrate of free prostate specific antigen 53643-48-4D, Vindesine, conjugates with oligopeptide substrate of free prostate specific antigen 117091-64-2D, Etoposide phosphate, conjugates with oligopeptide substrate of free prostate specific antigen

Marshall 08/468161

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of prostate cancer using)